Royalty Pharma price to book ratio RPRX
Market value divided by the book value of the company's net assets, since 2020.
- Today, Nov 3, 2026
- 5.7×
- 6-year median
- 3.8×
- Against its 6-year history
- 99th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 2.1× to 5.9×
- Peer median
- 5.9×
Royalty Pharma's price to book ratio is 5.7× as of Nov 3, 2026.
That is above its 6-year median of 3.8×, higher than on 99% of days in the last 6 years.
Over that time it ranged from 2.1× in Dec 2024 to 5.9× in Mar 2021.
The median for 10 healthcare stocks of a similar size is 5.9×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.6× | 3.5× | 5.7× |
| 2025 | 3.5× | 2.2× | 3.6× |
| 2024 | 2.2× | 2.1× | 2.8× |
| 2023 | 2.7× | 2.5× | 4.1× |
| 2022 | 3.9× | 3.9× | 4.6× |
| 2021 | 4.2× | 3.8× | 5.9× |
| 2020 | 4.4× | 3.2× | 4.4× |
Against its peers
Companies in Healthcare nearest Royalty Pharma's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| RPRXRoyalty Pharma | 5.7× |
| BIIBBiogen | 2.0× |
| GEHCGE HealthCare Technologies | 3.3× |
| ONCBeOne Medicines | 7.8× |
| IQVIQVIA | 6.9× |
| ZTSZoetis | 10.9× |
| ILMNIllumina | 12.6× |
| MTDMettler-Toledo International | n/m |
| RMDResMed | 4.9× |
| WATWaters | 3.1× |
| MDLNMedline | n/m |
| Peer median | 5.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Royalty Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.